Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race.

The global Prostate Cancer Treatment Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Prostate Cancer Treatment Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Prostate Cancer Treatment Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Prostate Cancer Treatment Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Prostate Cancer Treatment Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Tolmar
Astellas Pharma
AstraZeneca
Ferring Pharmaceuticals
Johnson & Johnson
Abbott
Sanofi
Ipsen
Novartis
Bayer

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Enzalutamid
Abiraterone
Leuprolide
Goserelin
Triptorelin
Histrelin
Degarelix
Sipuleucel-T
Docetaxel
Cabazitaxel

Segment by Application
Hospital
Research Institution
Clinic
Drugstore